ANI Pharmaceuticals, Inc. (ANIP) News
Filter ANIP News Items
ANIP News Results
|Loading, please wait...|
ANIP News Highlights
- For ANIP, its 30 day story count is now at 11.
- Over the past 14 days, the trend for ANIP's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about ANIP are DRUG, MG and BASE.
Latest ANIP News From Around the Web
Below are the latest news stories about ANI PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ANIP as an investment opportunity.
ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
BAUDETTE, Minn., May 22, 2023--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Jefferies Healthcare Conference in New York City as follows:
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Compugen (CGEN) have performed compared to their sector so far this year.
ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
BAUDETTE, Minn., May 16, 2023--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) ("ANI" or the "Company") today announced the closing of its previously announced underwritten public offering. A total of 2,183,545 shares of its common stock were sold at a public offering price of $39.50 per share, inclusive of the exercise in full of the underwriters’ option to purchase an additional 284,810 shares of common stock. The gross proceeds of the offering to the Company are approximately $86.25 million, before
ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity
BAUDETTE, Minn., May 15, 2023--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Applications (ANDAs) for Methsuximide Capsules USP, 300 mg and Alendronate Sodium Oral Solution 70 mg (base)/75 mL. Methsuximide Capsules has been granted 180-day Competitive Generic Therapy (CGT) Exclusivity, and Alendronate Sodium Oral Solution is eligible for CGT Exclusivity upon launch.
ANI Pharmaceuticals Announces Pricing of $75 Million Public Offering of Common Stock
BAUDETTE, Minn., May 12, 2023--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) ("ANI" or the "Company") today announced the pricing of its previously announced underwritten public offering of 1,898,735 shares of its common stock at a public offering price of $39.50 per share. The gross proceeds of the offering to the Company are expected to be $75 million, before deducting the underwriting discounts and commissions and other offering expenses. In addition, ANI granted the underwriters a 30-day option t
ANI Pharmaceuticals Announces Proposed Public Offering of Common Stock
BAUDETTE, Minn., May 11, 2023--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) ("ANI") today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by ANI. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, ANI intends to grant the underwriters a 30-da
Q1 2023 ANI Pharmaceuticals Inc Earnings Call
Q1 2023 ANI Pharmaceuticals Inc Earnings Call
Stocks Reverse Gains Ahead Of Slew Of Inflation Data
Stocks are lower this afternoon, as investors await a deluge of inflation data amid a rally for the banking sector.
Why ANI Pharmaceuticals Stock Is Soaring Today
ANI Pharmaceuticals Inc's (NASDAQ: ANIP) Q1 revenues were $106.8 million, +65.6% Y/Y, beating the consensus of $83.49 million. Net revenues for generic pharmaceutical products were $63.7 million, up 29.7%, driven by increased volume from the annualization of 2022 launches and a favorable product mix. Net revenues of rare disease pharmaceutical products, which consist entirely of sales of Cortrophin Gel, were $16.3 million, in-line with the company's expectations. Adjusted EPS of $1.17, a turnaro
ANI Pharmaceuticals (ANIP) Beats Q1 Earnings and Revenue Estimates
ANI (ANIP) delivered earnings and revenue surprises of 244.12% and 28.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?